XOMA (NASDAQ:XOMA) Earns “Buy” Rating from HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $123.00 price target on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 377.67% from the stock’s previous close.

Separately, StockNews.com lowered shares of XOMA from a “hold” rating to a “sell” rating in a report on Friday, December 27th.

XOMA Price Performance

XOMA traded down $0.52 on Tuesday, reaching $25.75. The stock had a trading volume of 10,351 shares, compared to its average volume of 28,983. The firm has a 50-day moving average of $29.41 and a 200-day moving average of $27.95. XOMA has a fifty-two week low of $18.57 and a fifty-two week high of $35.00. The company has a market capitalization of $303.41 million, a price-to-earnings ratio of -7.40 and a beta of 0.92. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

Insiders Place Their Bets

In other news, CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the transaction, the chief executive officer now directly owns 34,979 shares in the company, valued at $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets boosted its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the last quarter. Geode Capital Management LLC lifted its holdings in XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after buying an additional 1,138 shares during the period. Rhumbline Advisers boosted its position in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares during the last quarter. State Street Corp boosted its position in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after acquiring an additional 1,968 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.